Monogram Technologies
Austin, Texas developer of AI-driven orthopedic robots for knee replacement, acquired by Zimmer Biomet in October 2025.
Monogram Technologies, which listed on Nasdaq as Monogram Orthopaedics, is based in Austin, Texas, and develops AI-driven orthopedic robotics with semi-autonomous and fully autonomous technologies. Its CT-based semi-autonomous robot for total knee arthroplasty received FDA 510(k) clearance in March 2025, and the company began clinical testing of a fully autonomous version in July 2025. At the time of its listing it described its work as patient-optimized, 3D-printed orthopedic implants enabled by robotics and pre-operative imaging. In May 2023 it closed a Regulation A+ offering of 2,374,641 shares at $7.25 each for gross proceeds of $17,216,147, with Digital Offering as lead managing selling agent, and its shares began trading on Nasdaq under MGRM on May 18, 2023. In October 2024 it closed an upsized offering of 5,790,479 units, each made up of one share of 8.00% Series D Convertible Cumulative Preferred Stock and one warrant, for gross proceeds of approximately $13 million, again with Digital Offering as lead selling agent. In July 2025 Zimmer Biomet agreed to buy Monogram for $4.04 per share in cash plus a contingent value right worth up to $12.37 per share if product development, regulatory and revenue milestones are met through 2030, an upfront equity value of approximately $177 million. Zimmer Biomet completed the acquisition on October 7, 2025, and Monogram shares stopped trading on Nasdaq that day.
- Latest funding
- —
- Total funding
- $17.2M
- Latest valuation
- —
- Founded
- —
- Country
- United States
- Oct 2, 2024Preferred stock offering—
- May 17, 2023IPO (Regulation A+)$17.2M